Použití dalbavancinu při aplikaci dermální náhrady

Stáhnout PDF

Autoři: Lipový B. ¹; Hladík M. ¹; Linhartová Bořilová P. ^2,3,4,5,6; Hanslianová M. ⁷
Působiště autorů: University Hospital Brno, Department of Burns and Plastic Surgery, Brno, Czech Republic ¹; Masaryk University, Faculty of Medicine, Institute of Medical Genetics, Brno, Czech Republic ²; Masaryk University, Faculty of Medicine, Department of Pathophysiology, Brno, Czech Republic ³; Masaryk University, Faculty of Medicine, Department of Stomatology, Brno, Czech Republic ⁴; University Hospital Brno, Clinic of Oral, Jaw and Facial Surgery, Brno, Czech Republic ⁵; Masaryk University, Faculty of Pharmacy, Department of Molecular Pharmacy, Brno, Czech Republic ⁶; University Hospital Brno, Department of Clinical Microbio logy, Brno, Czech Republic ⁷
Vyšlo v časopise: ACTA CHIRURGIAE PLASTICAE, 63, 1, 2021, pp. 14-17
doi: https://doi.org/10.48095/ccachp202114

Zdroje

1. Shahrokhi S., Arno A., Jeschke MG. The use of dermal substitutes in burn surgery: acute phase. Wound Repair Regen. 2014, 22: 14–22.

2. Haslik W., Kamolz LP., Nathschläger G., Andel H., Meissl G., Frey M. First experiences with the collagen-elastin matrix Matriderm as a dermal substitute in severe burn injuries of the hand. Burns. 2007, 33: 364–8.

3. Ramsay ID., Török ME., Skin and soft tissue infections. Medicine. 2017, 45: 699–706.

4. Abbas M., Paul M., Huttner A. New and improved? A review of novel antibiotics for Gram-positive bacteria. Clin Microbiol Infect. 2017, 23: 697–703.

5. Bouza E., Valerio M., Soriano A., Morata L., Carus EG., Rodríguez-González C., Hidalgo-Tenorio MC., Plata A., Muñoz P., Vena A. DALBUSE Study Group (Dalbavancina: Estudio de su uso clinico en España). Dalbavancin in the treatment of different gram-positive infections: a real-life experience. Int J Antimicrob Agents. 2018, 51: 571–7.

6. Wunsch S., Krause R., Valentin T., Prattes J., Janata O., Lenger A., Bellmann-Weiler R., Weiss G., Zollner-Schwetz I. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections. Int J Infect Dis. 2019, 81: 210–14.

7. Escola-Verge L., Los-Arcos I., Almirante B. New antibiotics for the treatment of infections by multidrug-resistant microorganisms. Medicina Clínica (English Edition). 2020, 154: 351–7.

8. Almangour TA., Perry KG., Alhifany AA. Dalbavancin versus standard of care for the treatment of osteomyelitis in adults: A retrospective matched cohort study. Saudi Pharmaceutical Journal. 2020, 28: 460–4.

9. Chen AY., Zervos MJ., Vazquez JA. Dalbavancin: a novel antimicrobial. Int J Clin Pract. 2007, 61: 853–63.

10. Durojaiye OC., Bell H., Andrews D., Ntziora F., Cartwright K. Clinical efficacy, cost analysis and patient acceptability of outpatient parenteral antibiotic therapy (OPAT): a decade of Sheffield (UK) OPAT service. Int J Antimicrob Agents. 2018, 51: 26–32.

11. Almangour TA., Perry GK., Terriff CM., Alhifany AA., Kaye KS. Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utility. Diagn Microbiol Infect Dis. 2019, 93: 213–18.